Total submissions: 2
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Gene |
RCV000255137 | SCV000322298 | pathogenic | not provided | 2016-03-18 | criteria provided, single submitter | clinical testing | The G46D pathogenic variant in the YARS2 gene has been reported previously in the homozygous state in two individuals with mitochondrial respiratory chain complex defects (Sasarman et al., 2012; Taylor et al., 2014). Immunoblot analysis for one of these individuals demonstrated that the G46D variant generates undetectable levels of YARS2 protein in myoblasts and myotubes and results in a generalized mitochondrial translation defect (Sasarman et al., 2012). This variant was not observed in approximately 6500 individuals of European and African American ancestry in the NHLBI Exome Sequencing Project, indicating it is not a common variant in these populations. The G46D variant is a non-conservative amino acid substitution, which is likely to impact secondary protein structure as these residues differ in polarity, charge, size and/or other properties. This substitution occurs at a position that is conserved across species, and in silico analysis predicts this variant is probably damaging to the protein structure/function. We interpret G46D as a pathogenic variant. |
| OMIM | RCV000088671 | SCV000121593 | pathogenic | Myopathy, lactic acidosis, and sideroblastic anemia 2 | 2012-08-01 | no assertion criteria provided | literature only |